Immunogenicity And Safety Of Adenovirus-Based Vector Vaccines For COVID-19

Abstract

Background: The literature review on the immunogenicity and safety of adenovirus-based vector vaccines for COVID-19 presents a detailed examination of various studies that contribute to understanding the effectiveness and safety profiles of these vaccines. Literature Review: The systematic review conducted by (A. R. Mohamed Hussein et al., 2022) emphasizes that the benefits of adenovirus-based vaccines, particularly in preventing severe COVID-19, outweigh the risks, while also calling for ongoing safety monitoring. This sentiment is echoed in the work of , which underscores the importance of understanding both humoral and cell-mediated immune responses in evaluating vaccine efficacy. Moreover, the implications of pre-existing immunity and the potential for enhanced immune responses through heterologous vaccination regimens, as discussed by (Sáez-Llorens et al., 2023), add another layer of complexity to the evaluation of these vaccines. The findings by (Scarsella et al., 2024) regarding the advantages of adenoviral vectors in activating innate immune responses without adjuvants further highlight their potential in vaccine design. Additionally, the investigation into T-cell responses and the incidence of vaccine-induced immune thrombotic thrombocytopenia by (Gardner et al., 2024) serves as a reminder of the need for continuous research into the immunogenic profiles of these vaccines to ensure safety across diverse populations. Conclusion: In conclusion, the collective findings from these studies indicate that adenovirus-based vector vaccines for COVID-19 are promising candidates due to their robust immunogenicity and generally favorable safety profiles. However, the emergence of rare adverse events, particularly thrombosis, necessitates ongoing research and monitoring to fully understand the safety implications of these vaccines as they are deployed in broader public health contexts.